Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Momentum now, May 25 (ASCO reveal) and After

<< Previous

Bullboard Posts

Next >>

Comment by Buckhenryon May 09, 2023 9:28am

145 Views

Post# 35438214

RE:RE:Momentum now, May 25 (ASCO reveal) and After

Not sure why folks like to make predictions like this but it seems to run rampant on here. Maybe if it comes true then they feel they can pat themselves on the back. Need to stick yo things you know not pie in the sky stuff.

<< Previous

Bullboard Posts

Next >>

B2Gold stock buckles under news of labour strike in Mali